Hot Investor Mandate: Western Europe-Based VC Invests Opportunistically in All Life Science Sectors in CNS, Nephrology, Dermatology and More in North America & Europe

4 Aug

A VC based in Western Europe invests opportunistically within the indications of nephrology, dermatology, urology, CNS/brain and orphan indications. The firm invests in companies from seed-Series A, up to 2M EUR. The firm is currently focused on European companies, but may consider companies based in North America as well.

Within the indications of interest, the firm is willing to consider companies in all sectors, therapeutics, medical devices, diagnostics and digital health. For therapeutic companies, the firm prefers the companies have some preclinical data, and be about a year from initiating clinical trials. For diagnostics companies, The firm prefers the companies be no more than 1 year from commercialization.

The firm can both lead or co-invest, and they may or may not take a board seat, depending on how they can help the company. The firm believes in promoting gender equality, and a large number of their investments are in female-led startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: